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2Abstract
Background: A repeat biopsy is recommended, but often omitted in coeliac disease patients on
a gluten-free diet. The effect of performing or not performing repeat biopsies is currently
unknown.
Aim: To identify factors associated with and the significance of lacking biopsy for long-term
outcome. Predictors and the importance of incomplete histological recovery after one year was
investigated in re-biopsied patients.
Methods: 760 patients participated in a nationwide follow-up study. Medical data were gathered
via interviews and patient records, and blood samples were drawn for serology. Current
symptoms and well-being were assessed by validated PGWB, SF-36 and GSRS questionnaires.
Results: Malabsorption was more common among those with a repeat biopsy (46%) than those
without repeat biopsy (33%), p<0.001, as were severe symptoms at diagnosis (24% vs 16%,
P=0.05) and concomitant gastrointestinal (40% vs 32%, P=0.049) or musculoskeletal (35% vs
27%, P=0.023) diseases such as arthritis, osteoporosis and back pain. Repeat biopsy was more
rare in subjects diagnosed in private care (11% vs 23%, P<0.001) or by screening (10% vs 16%,
P=0.010). The groups were comparable as to current symptoms and dietary adherence, but those
without re-biopsy were less confident of their diet (89% vs 94%, P=0.002) and more often
seropositive on diet (14% vs 9%, P=0.012). They reported better SF-36 physical functioning
(P=0.043) and less pain and indigestion (P=0.013 and P=0.046 respectively) and total GSRS
(P=0.052) score. Incomplete mucosal recovery was predicted by more advanced histological
(P<0.001) and serological (P=0.001) disease at diagnosis, while the groups did not differ in
current adherence, symptoms, seropositivity and questionnaire scores.
Conclusion: Severe disease at diagnosis predicted the record of a repeat biopsy and incomplete
mucosal recovery. Neither lacking biopsy nor incomplete recovery in a relative short time span
of one year was associated with poorer long-term outcome.
3Introduction
A careful follow-up of coeliac disease activity after the initial diagnosis is considered important
due to the possible complications associated with incomplete healing of the small-bowel
mucosa 1, 2. Owing to the lack of sensitive surrogate markers for histological recovery, most
current guidelines recommend a repeat biopsy to be considered on a gluten-free diet 1-6, this
often being executed approximately one year after the diagnosis, even if there is lack of
evidence on the effect of such practice3, 7-9. On the other hand, due to its unpleasantness and
resource-consuming nature, the control endoscopy is often omitted in clinical practice, the
effect of this on long-term outcomes being currently unknown 7. Altogether, due to the scarcity
of evidence, this topic has been under active discussion in the expert guidelines 1.
Even if a repeat biopsy is conducted, the significance of possible incomplete
villous recovery on dietary treatment remains scantly studied. It has been linked, for example,
to rare cases of refractory coeliac disease and lymphoproliferative malignancies, but the
relevant results appear to be markedly dependent in a fifteen-year follow-up on the study
population and the timing of the endoscopy 1,3,8,9,11,12. We have in fact recently shown that
incomplete histological recovery after one year on a gluten-free diet is not associated with
reduced short-term well-being or increased risk of cancer and mortality 8. Further, although
after one year’s diet up to 50% of coeliac patients may show signs of villous damage, in the
long run this is seen in less than 10% of cases and only 0.3% have true refractory coeliac disease
8,10,12.
The rapidly growing number of coeliac disease patients renders optimal targeting
and timing of the endoscopic follow-up a major public health issue 8,9,10,12. To further elucidate
these aspects, we investigated factors associated with the omission of routine a invasive follow-
up and the value of a repeat biopsy one year after diagnosis with respect to long-term outcome.
Simultaneously we were able to further explore the significance of incomplete histological
recovery found in the follow-up biopsy in a nationwide coeliac disease cohort.
4Materials & Methods
Patients and study design
The nationwide cross-sectional study was conducted in Tampere University Hospital and the
University of Tampere. The participants were recruited via newspaper advertisements and with
the help of local and national coeliac disease societies. Inclusion criteria were age ≥18 years
and a biopsy-proven coeliac disease diagnosis at least two years before the present study. All
voluntary participants completed validated questionnaires for current symptoms and health-
related quality of life and were interviewed systematically by an experienced physician or study
nurse. In addition, blood samples were drawn for serology and medical records reviewed in
order to confirm the diagnosis and to complement clinical data and laboratory parameters.
Subjects with unclear coeliac disease diagnosis or substantially lacking medical information
were excluded. The possible use of olmesartan therapy was also checked for and considered an
exclusion criterion, as it may cause severe enteropathy resembling coeliac disease 13.
After collection of study data the results were compared between subgroups of
participants who had either undergone (Repeat biopsy) or not (No repeat biopsy) a routine
follow-up biopsy approximately one year after the coeliac disease diagnosis. For similar
comparison, subjects who had been re-biopsied while on a gluten-free diet were categorized
into those with complete and those with incomplete histological recovery after one year on the
diet.
The study enrolment and collection of personal information, blood samples and
medical data were conducted with the permission and according to the guidelines of the Ethical
Committee of the Pirkanmaa Hospital District. All participants gave written informed consent.
Clinical characteristics
5The following clinical and demographic data was collected from all participants: gender, age at
present and at diagnosis, clinical presentation at diagnosis, the type (gastrointestinal symptoms,
extra-intestinal symptoms, screen-detected), duration and severity of symptoms before
diagnosis and also their current persistence, family history of coeliac disease, possible
symptoms in childhood, presence of coeliac disease-associated and other significant chronic
comorbidities, and site (primary, secondary or tertiary care, private care) of coeliac disease
diagnosis. Severity of symptoms was further categorized as mild, moderate and severe as
previously described in detail 14.
Small-bowel mucosal biopsies
Data on the biopsies were collected from patient records. Our national guidelines recommend
at least four small-bowel mucosal biopsies to be taken routinely from each patient upon coeliac
disease suspicion and during the repeat endoscopy. The histological specimens are forwarded
to the hospitals’ pathology department, where the severity of mucosal damage is evaluated in
representative biopsy cuttings. In the present study the severity of mucosal lesion was at
diagnosis graded into normal, partial, subtotal or total villous atrophy based on the original
pathology report. Mucosal recovery on gluten-free diet was defined morphologically based on
normalized villous height to crypt depth ratio.
Serology and hemoglobin
The values of serum endomysial antibodies at time of diagnosis, if available, were gathered
from patient files. Further serum endomysial antibodies and transglutaminase 2 antibodies were
measured in all subjects at the time of the study while on a strict gluten-free diet. Serum IgA-
class serum transglutaminase-2 antibodies were tested by commercial enzyme-linked
immunosorbent assay (QUANTA Lite h-tTG IgA, INOVA Diagnostics, San Diego, CA).
Values >30.0 U/ were rated positive according to the manufacturer’s instructions. Serum
6endomysial antibodies were assessed by indirect immunofluorescence on human umbilical cord
15 . Serum endomysial antibodies titers 1: ≥5 were considered positive and diluted until negative
to 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 and 1:4000. The values were further sub-
categorized into low (titers 1:5-1:200) and high positive (1:500-1:4000). In cases of selective
IgA deficiency the corresponding IgG-class antibodies were measured. Blood hemoglobin
values and the possible presence of anemia at coeliac disease diagnosis were gathered from the
medical files.
Adherence to the gluten-free diet
Provision of professional dietary advice at coeliac disease diagnosis was verified by patient
interview and from the patient records. Current self-reported long-term adherence to the gluten-
free diet was inquired and classified as “strict” (minor inadvertent lapses less than a few times
a year), “occasional lapses” (lapses less frequently than once per month) and “normal diet”
(more frequent lapses) 16,17. Alongside adherence, also the patient’s overall competency to
manage the diet and the possible use of purified oats and wheat starch products were asked 18
,19. Long-term dietary adherence was further estimated on the basis of coeliac antibody
positivity at the time of the present study.
Questionnaires
All questionnaires were filled in at the time of the current study on a long-term gluten-free diet.
Short Form 36 Health Survey (SF-36) and Psychological General Well-Being questionnaires
(PGWB) were used to assess patients’ self-perceived quality of life and gastrointestinal
symptoms over time up to the current study. SF-36 comprises of 36 separate questions which
can be divided into eight domains as follows; physical functioning, role limitations due to
physical problems, bodily pain, general health, vitality, social functioning, role limitations due
7to emotional problems and mental health 10,20 ,21,22-24 . Items are re-scored from 0 to 100, higher
scores indicating better health and quality of life.
PGWB is a well-validated and widely used questionnaire both in general and in
coeliac disease 15,16,22,25. The 22 separate items can be further divided into six sub-dimensions
measuring anxiety, depression, well-being, self-control, general health, and vitality. All items
use a 6-grade Likert scale with higher scores representing better well-being and quality of life.
Self-perceived severity of gastrointestinal symptoms was evaluated by the
Gastrointestinal Symptom Rating Scale (GSRS) questionnaire 15,26 . This comprises of 15
separate items which can be added together as a total score and divided into 5 sub-dimensions
measuring abdominal pain, gastro-esophageal reflux, indigestion, diarrhea and constipation.
The scoring is based on a 7-grade Likert scale, higher scores reflecting more severe
gastrointestinal symptom.
Statistical analysis
Continuous variables and questionnaire findings are presented as medians with quartiles or
ranges. Binominal and categorical variables are presented as number of subjects and
percentages. Continuous variables were studied using Mann-Whitney test and binominal and
classified variables using Chi-square test. A p-value <0.05 was considered significant in all
analyses. Statistical analyses were made using the Statistical Package for the Social Sciences
version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0.
Armonk, NY: IBM Corp.)
Results
Altogether 791 participants (median age at diagnosis 44 years, females 78%) had confirmed
coeliac disease and were enrolled for further analyses. However, 27 of them were excluded
because it was unclear whether they had undergone a repeat biopsy and four due to use of
8olmesartan. Of the final cohort of 760 participants 516 (68%) had (Repeat biopsy group) and
244 (32%) had not (No repeat biopsy group) undergone a follow-up endoscopy after a median
of one year.
Factors predicting record of a repeat biopsy
Patients with severe clinical or histological presentation or signs of malabsorption at diagnosis
were more likely to undergo a repeat biopsy, whereas it was less common among those
diagnosed in private care or by screening (Table 1). Record of a histological follow-up was not
associated with the duration or type of symptoms and serum endomysial antibodies titers at
diagnosis, gender, presence of symptoms during childhood and family history of coeliac disease
(Table 1). Median age at diagnosis was also comparable in subjects with and without repeat
biopsy (53 vs 55 years, p = 0.885)
Long-term follow-up data on patients with and without a repeat biopsy
The median time on a gluten-free diet prior to the current study was eight years. Coeliac disease
patients who had undergone a repeat biopsy were more often found to suffer had from
concomitant Sjögren’s syndrome, musculoskeletal disease or gastrointestinal disease (Table 2).
There were no significant differences between the groups in the prevalence of other chronic
conditions (Table 2).
Both study groups had received comparable dietary advice at diagnosis and
showed equal adherence at time of inquiry (Table 3), but those with no repeat biopsy after one
year were less confident as to their current capability to manage a strict diet. Further, the non-
biopsied subjects had significantly, even if only modestly, higher serum endomysial antibodies
titers on a long-term gluten-free diet. There was, however, no difference between the groups in
the presence or severity of current self-estimated symptoms (Table 3), and, based on the GSRS
questionnaire, patients without repeat biopsy had even fewer overall gastrointestinal symptoms
9and less indigestion (Table 4). There were also no differences between the groups in respect of
most current health and quality of life measurements except that subjects without a repeat
biopsy reported better SF-36 physical functioning and bodily pain scores (Table 4).
Predictors of incomplete villous recovery in re-biopsied subjects
The result of the re-biopsy was available in 476 (92%) out of the 516 patients undergoing the
procedure after one year after diagnosis. Altogether 276 (58%) had reached morphological
small-bowel mucosal recovery, while in 200 (42%) it remained incomplete. Factors predicting
incomplete recovery were malabsorption (55% vs 41%, p = 0.003), high serum endomysial
antibodies titer (46% vs 25%, p < 0.001) and severe mucosal damage (total atrophy 32% vs
19%, p < 0.001) at diagnosis. The recovery and non-recovery groups did not differ in gender,
age at diagnosis, family history of coeliac disease, site of diagnosis, severity and duration of
symptoms before diagnosis, or presence of symptoms in childhood (data not shown). There was
also no difference between the groups in hemoglobin at diagnosis, when analyzed with both
genders together, but in separate analysis the median value was lower in women evincing no
recovery (12.3 g/dl vs 12.7 g/dl, p = 0.030).
Long-term outcomes in re-biopsied patients with and without histological recovery
Coeliac disease patients with incomplete mucosal recovery one year after diagnosis had more
concomitant respiratory (15 vs 22%, p=0.031) and dermatological diseases (17 vs 10%, p =
0.043) at current evaluation, while there was no differences in the frequency of coeliac disease-
associated and other chronic diseases. Further, the recovery and non-recovery patients showed
similar severity of current gastrointestinal symptoms and quality of life as measured by the
questionnaires (data not shown). The groups had also received equally much dietary advice at
diagnosis and did not differ in current adherence or capability to manage the diet, in record of
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regular follow-up, or in use of purified oats and prevalence of serum transglutaminase-2
antibody positivity (Table 5).
Discussion
The main finding in the present study was that patients with or without endoscopic follow-up
did not differ in severity of symptoms or in well-being after a median follow-up time of almost
a decade. In addition, the repeat biopsy and no biopsy groups showed excellent and comparable
self-reported dietary adherence. Finally, even if a repeat biopsy had been conducted, incomplete
mucosal recovery one year after diagnosis did not affect the long-term clinical outcomes.
A repeat biopsy after one year was undertaken especially for patients with severe
presentation at diagnosis, while it was more often omitted in screen-detected cases. It would
seem logical that, as also seen in other chronic diseases 27, physicians are keener to follow sicker
patients with an increased risk of long-term complications. Alternatively, those with milder or
screen-detected disease are likely to be less willing to undergo an unpleasant repeat biopsy and,
in turn, physicians neglect it in view of to the anticipated better prognosis. This may also explain
the similar tendency to omit the repeat biopsy in type 1 diabetes patients, whose coeliac disease
is often found by screening and who might have an increased risk of endoscopic complications
28. Repeat biopsies were also more often taken from patients with concomitant gastro-intestinal
and musculoskeletal illnesses, strengthening the conception that those with comorbidities and
ongoing symptoms undergo the procedure with a lower threshold.
We also found patients diagnosed in the private sector to have the repeat biopsy
omitted more often than those followed in public healthcare. This might be because in private
care patients have to pay for the second endoscopy themselves. In addition, in Finland
healthcare has evolved around a strong public sector which, as also seen in the present study,
treats most coeliac disease patients. In contrast, the private sector is more focused on frontline
screening and refers the putative patients to public healthcare for further diagnosis and follow-
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up30. The results would very likely differ in countries where a system of private health
insurances predominates, as in the USA29,30. What is more, we found no differences in the rate
of re-biopsy between public healthcare levels. This somewhat unexpected finding might be
explained by the organized decentralization of coeliac disease diagnostics and the use of
uniform nationwide guidelines at all healthcare levels in Finland 28,31. In fact, nowadays up to
85% of Finnish coeliac disease patients are diagnosed and followed in primary and secondary
care 31.
Interestingly, based on the GSRS, coeliac disease patients with a repeat biopsy
after one year also remained more symptomatic during the current long-term follow-up. One
reason for this may be the aforementioned higher prevalence of gastrointestinal comorbidities
in this group. In addition, we have shown that patients with severe presentation at diagnosis are
also more likely to remain symptomatic on a long-term gluten-free diet 34. Likewise, here those
with repeat biopsy had currently more bodily pain and decreased physical functioning, again
probably since they have more musculoskeletal comorbidities. In contrast, the groups did not
differ in any of the PGWB sub-dimension scores, indicating that the minor differences seen in
the prevalence of symptoms and comorbidities have no major effect on self-perceived well-
being and quality of life.
Another important finding was that the omission of a repeat biopsy one year after
the diagnosis did not affect long-term dietary adherence. This suggests that the invasive follow-
up does not play a major role in commitment to the gluten-free diet, at least in Finland, where
adherence is generally very good and the additional costs of the diet remain reasonable 2,33,35.
Nevertheless, patients without a repeat biopsy considered their capability to manage their diet
lower and were somewhat more often seropositive, indicating that a subgroup of patients might
benefit from the endoscopic follow-up 34. Then again, it might be worthwhile investigating
whether the re-biopsy is in fact the main issue here or whether other means of follow-up
combined with enhanced dietary counselling would be equally effective 36-39.
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We also sought to identify associated factors and the long-term significance of
incomplete histological recovery one year after coeliac disease diagnosis in a nationwide
cohort. As with the repeat biopsy, incomplete recovery was predicted by more severe disease
presentation at diagnosis. Similar associations between advanced disease and incomplete
recovery on treatment have previously been observed in smaller studies 3,8,40,41. Further, we
recently showed that more ill patients need a longer time to reach complete mucosal recovery13.
Hence there still was villous atrophy in as many as 42% of the patients here after one year on
gluten-free diet. Notwithstanding the differences in the speed of mucosal recovery, long-term
damage is present in only 4-6% of patients, a fraction of what is seen after one year11,33,42,43.
Moreover, no more than 0.3% have true refractory coeliac disease31. It must be emphasized that
incomplete recovery is not explained by dietary lapses since, in line with previous findings by
the present group9 and Haere and associates 37, also the majority of those without mucosal
healing showed excellent adherence to the gluten-free diet.
Notably, the recovery and non-recovery groups did not differ in the prevalence of
malignancies. This was in line with our previous study carried out on a different patient cohort
in a tertiary center setting8 and provides an interesting contribution to discussion of the risk of
malignancies and the necessity of a repeat biopsy. In contrast to our results, Lebwohl and
colleagues44 found an increased risk of lymphoproliferative malignancies in patients with
persistent villous atrophy, even if this could only be seen in those diagnosed before the year
2000. This controversy might be explained by differences in study design and duration of
follow-up and improvements in the diagnostics and management of coeliac disease during the
past decades. Since what is involved is a rare complication it is also possible that statistical
significance was not reached by chance only.
The only significant long-term difference between subjects with or without
histological recovery was the higher prevalence of dermatological and respiratory comorbidity
in the latter group. In particular, there was no difference in gastro-intestinal symptoms or
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general well-being even in the long run, which is in accord with our previous short-term
findings8 in a tertiary center. This strengthens the conception that slower mucosal recovery does
not directly affect the improvement of symptoms and quality of life in patients on a strict gluten-
free diet. The reason for poorer recovery among those with concomitant skin and respiratory
diseases is unclear and remains a subject for further studies.
Our major strength here was the large number of representative patients diagnosed
at different levels of health care. We also succeeded in collecting a wide variety of relevant
study parameters, and the use of validated questionnaires increases the reliability and
reproducibility of results. A limitation is that evaluation of the repeat biopsies was not
centralized 45. Further, the recruitment of most of the participants through coeliac societies may
increase the risk of selection bias. The analysis of in particular serious outcomes such as
malignancy according to follow-up histology has also the potential for survival bias, as
sampling was not done at the time of the repeat biopsy. Finally, we were not able to compare
mortality between the groups, since we did not take a certain pre-defined sample but instead
enrolled existing patients.  Lack of histological follow-up and incomplete mucosal recovery
might be associated with increased mortality 9,38, and more studies are needed to further
elucidate this issue.
In conclusion, coeliac disease patients with severe initial presentation were more
prone to undergo a repeat biopsy after one year on diet and were also found to lack full mucosal
recovery if re-biopsied. However, neither the lack of the re-biopsy nor histological recovery
was reflected in long-term clinical outcomes and dietary adherence. Based on these results,
performing a routine endoscopy one year after diagnosis is not necessarily an optimal approach.
Instead, we propose a more personalized follow-up, wherein the repeat biopsy is conducted
later, after 2-5 years and only for a selected group based on age, initial disease severity and
response to the gluten-free diet.
14
AUTHORSHIP
Guarantor of the article: Kalle Kurppa
Author contributions: Henna Pekki: Data analysis, data interpretation, drafting of the
manuscript. Kalle Kurppa: Data acquisition, data interpretation, critical revision of the
manuscript for important intellectual content. Markku Mäki: Data interpretation, critical
revision of the manuscript for important intellectual content. Heini Huhtala: Data analysis,
data interpretation, critical revision of the manuscript for important intellectual content. Kaija
Laurila: Data interpretation, critical revision of the manuscript for important intellectual
content. Tuire Ilus: Data interpretation, critical revision of the manuscript for important
intellectual content. Katri Kaukinen: Data interpretation, critical revision of the manuscript
for important intellectual content
All authors approved the final version of the manuscript.
ACKNOWELEDGEMENTS
This study was supported by the Academy of Finland, the Sigrid Juselius Foundation, the
Competitive State Research Financing of the Expert Area of Tampere University Hospital, the
Finnish Medical Foundation, the Mary and Georg Ehrnrooth Foundation, and the Foundation
for Pediatric Research
15
References
1. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease:
Guidelines from the British society of gastroenterology. Gut. 2014; 63: 1210-28.
2. Kaukinen K, Lindfors K, Collin P, Koskinen O, Maki M. Coeliac disease--a diagnostic and
therapeutic challenge. Clin Chem Lab Med. 2010; 48: 1205-1216.
3. Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA. Mucosal recovery and
mortality in adults with celiac disease after treatment with a gluten-free diet. Am J
Gastroenterol. 2010; 105: 1412-20.
4. Kurppa K, Taavela J, Saavalainen P, Kaukinen K, Lindfors K. Novel diagnostic techniques
for celiac disease. Expert Rev Gastroenterol Hepatol. 2016; 10: 795-805.
5. Bai JC, Fried M, Corazza GR, et al. World Gastroenterology Organisation guidelines on
celiac disease. J Clin Gastroenterol. 2013;47:121-6.
6. Kelly CP, Bai JC, Liu E, Laffler DA. Advances in diagnosis and management of celiac
disease. Gastroenterology. 2015;148:1175-86.
7. Herman ML, Rubio-Tapia A, Lahr BD, Larson JJ, Van Dyke CT, Murray JA. Patients with
celiac disease are not followed up adequately. Clin Gastroenterol Hepatol. 2012; 10: 893-9.
8. Pekki H, Kurppa K, Maki M, et al. Predictors and significance of incomplete mucosal
recovery in celiac disease after 1 year on a gluten-free diet. Am J Gastroenterol. 2015; 110:
1078-85.
9. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and mortality in coeliac disease.
Aliment Pharmacol Ther. 2013; 37: 332-9.
10. Haere P, Hoie O, Schulz T, Schonhardt I, Raki M, Lundin KE. Long-term mucosal
recovery and healing in celiac disease is the rule - not the exception. Scand J Gastroenterol.
2016: 51: 1439-46.
16
11. Eigner W, Bashir K, Primas C, et al. Dynamics and occurence of refractory coeliac
disease and associated complications over 25 years. Aliment Pharmacol Ther. 2017;45:364-
72.
12. Tuire I, Marja-Leena L, Teea S, et al. Persistent duodenal intraepithelial lymphocytosis
despite a long-term strict gluten-free diet in celiac disease. Am J Gastroenterol. 2012; 107:
1563-9.
13. Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of
a national survey. Aliment Pharmacol Ther. 2014;40:1103-9
14. Kivela L, Kaukinen K, Lahdeaho ML, et al. Presentation of celiac disease in Finnish
children is no longer changing: A 50-year perspective. J Pediatr. 2015; 167: 1109-15.
15. Kurppa K, Paavola A, Collin P, et al. Benefits of a gluten-free diet for asymptomatic
patients with serologic markers of celiac disease. Gastroenterology. 2014; 147: 610-7.
16. Viljamaa M, Collin P, Huhutala H, Sievänen H, Mäki M, Kaukinen K. Is coeliac disease
screening in risk groups justified? A fourteen-year follow-up with special focus on
compliance and quality of life. Aliment Pharmacol Ther. 2005; 22: 317-24.
17. Lanzini A, Lanzarotto F, Villanacci V, et al. Complete recovery of intestinal mucosa
occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment
Pharmacol Ther. 2009; 29: 1299˗308.
18. Kaukinen K, Collin P, Huhtala H, Maki M. Long-term consumption of oats in adult celiac
disease patients. Nutrients. 2013; 5: 4380-9.
19. Kaukinen K, Collin P, Holm K, et al. Wheat starch-containing gluten-free flour products
in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study.
Scand J Gastroenterol. 1999; 34: 163-9.
20. Hallert C, Granno C, Hulten S, et al. Living with coeliac disease: Controlled study of the
burden of illness. Scand J Gastroenterol. 2002; 37: 39-42.
17
21. McHorney CA, Ware JEJr, Lu JF, Sherbourne CD. The MOS 36-item short-form health
survey (SF-36): III. tests of data quality, scaling assumptions, and reliability across diverse
patient groups. Med Care. 1994; 32: 40-66.
22. Hallert C, Granno C, Grant C, et al. Quality of life of adult coeliac patients treated for 10
years. Scand J Gastroenterol. 1998; 33: 933-8.
23. Viljamaa M, Collin P, Huhtala H, Sievanen H, Maki M, Kaukinen K. Is coeliac disease
screening in risk groups justified? A fourteen-year follow-up with special focus on
compliance and quality of life. Aliment Pharmacol Ther. 2005; 22: 317-24.
24. Ware JE,Jr, Gandek B. Overview of the SF-36 health survey and the international quality
of life assessment (IQOLA) project. J Clin Epidemiol. 1998; 51: 903-12.
25. Kurppa K, Paavola A, Collin P, et al. Benefits of a gluten-free diet for asymptomatic
patients with serologic markers of celiac disease. Gastroenterology. 2014; 147: 610-7.
26. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as
part of the documentation of quality of life instruments for use in upper gastrointestinal
disease. Scand J Gastroenterol Suppl. 1996; 221: 8-13.
27. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal
symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci.
1988; 33: 129-34.
28. van den Bemt L, Schermer TR, Smeele IJ, et al. An expert-supported monitoring system
for patients with chronic obstructive pulmonary disease in general practice: Results of a
cluster randomised controlled trial. Med J Aust. 2009; 191: 249-54.
29. Hakkinen U, Lehto J. Reform, change, and continuity in finnish health care. J Health Polit
Policy Law. 2005; 30: 79-96.
30. Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the united states,
germany and canada. Mater Sociomed. 2012; 24: 112-20.
18
31. Medford-Davis LN, Lin F, Greenstein A, Rhodes KV. "I broke my ankle": Access to
orthopedic follow-up care by insurance status. Acad Emerg Med. 2016.
32. Collin,P., Kaukinen, K., Mäki,M., et al. Käypähoito: Keliakia. 2011.
33. Ilus T, Kaukinen K, Virta LJ, et al. Refractory coeliac disease in a country with a high
prevalence of clinically-diagnosed coeliac disease. Aliment Pharmacol Ther. 2014; 39: 418-
25.
34. Hall NJ, Rubin G, Charnock A. Systematic review: Adherence to a gluten-free diet in
adult patients with coeliac disease. Aliment Pharmacol Ther. 2009; 30: 315-30.
35.Villafuerte-Galvez J, Vanga RR, Dennis M, et al. Factors governing long-term andherence
to a gluten-free diet in adult patients with celiac disease. Aliment Pharmacol Ther.
2015;42:753-60.
36. See JA, Kaukinen K, Makharia GK, Gibson PR, Murray JA. Practical insights into gluten-
free diets. Nat Rev Gastroenterol Hepatol. 2015; 12: 580-91.
37. Sainsbury K, Mullan B, Sharpe L. A randomized controlled trial of an online intervention
to improve gluten-free diet adherence in celiac disease. Am J Gastroenterol. 2013; 108: 811-
7.
38. Ludvigsson JF, Card T, Ciclitira PJ, et al. Support for patients with celiac disease: A
literature review. United European Gastroenterol J. 2015; 3: 146-59.
39. Leffler DA, Edwards George JB, Dennis M, Cook EF, Schuppan D, Kelly CP. A
prospective comparative study of five measures of gluten-free diet adherence in adults with
coeliac disease. Aliment Pharmacol Ther. 2007; 26: 1227-35.
40. Sharkey LM, Corbett G, Currie E, Lee J, Sweeney N, Woodward JM. Optimising delivery
of care in coeliac disease ? Comparison of the benefits of repeat biopsy and serological
follow-up. Aliment Pharmacol Ther. 2013; 38: 1278-91.
19
41. Abu Daya H, Lebwohl B, Lewis SK, Green PH. Celiac disease patients presenting with
anemia have more severe disease than those presenting with diarrhea. Clinical
Gastroenterology and Hepatology. 2013; 11: 1472-7.
42. Lebwohl B, Murray JA, Rubio-Tapia A et al. Predictors of persistent villous atrophy in
coeliac disease: a population-based study. Aliment Pharmacol Ther. 2014;488:95.
43. Galli G, Esposito G, Lahner E, et al. Histological recovery and gluten-free diet
andherence: a prospective 1-year follow-up study of adult patient with coeliac disease.
Aliment Pharmacol Ther. 2014;40:639-47
44. Lebwohl B, Granath F, Ekbom A, et al. Mucosal healing and risk for lymphoproliferative
malignancy in celiac disease. Ann Intern Med. 2013; 159:169-75.
 45. Taavela J , Koskinen O , Huhtala H et al. Validation of morphometric analyses of small-
intestinal biopsy readouts in celiac disease. PLoS One 2013; 8: e76163 .
Table 1. Clinical, serological and histological characteristics at diagnosis in 760 coeliac disease
patients without (No repeat biopsy) or with (Repeat biopsy) a follow-up biopsy done.
No  repeat
biopsy n=244
Repeat biopsy
n=516 P-value
n % n %
Females 181 74 413 80 0.093
Clinical presentation1
   Malabsorption 80 33 235 46 0.001
   Gastrointestinal symptoms 204 84 425 82 0.664
   Extraintestinal symptoms2 97 40 201 39 0.864
   Screen-detected 39 16 49 10 0.010
Duration of symptoms before diagnosis 0.571
>5 yr 96 42 209 43
<5 yr 119 50 245 50
Severity of symptoms at diagnosis 0.052
Severe 40 16 122 24
Moderate 100 41 216 42
Mild 91 37 158 31
No symptoms 13 5 18 4
Symptoms during childhood 72 28 181 35 0.223
Coeliac disease in family 146 63 329 64 0.790
Endomysial antibody titers at diagnosis 0.461
High 1: >200 36 39 77 35
Low 1:5-1:200 47 51 107 49
Negative 10 11 35 16
Severity of villous atrophy at diagnosis <0.001
Total 42 24 124 26
Subtotal 58 34 196 42
Partial 73 42 149 32
Site of diagnosis <0.001
Primary care 41 17 79 15
Private care 57 23 58 11
Secondary care 108 44 250 49
Tertiary care 38 17 125 24
1 Patient can present with more than one symptom
2Arthritis, dental enamel defects, dementia, dermatitis herpetiformis, glossitis, aphtous stomatitis,
gynecological problems, myopathy, neurologic symptoms, osteoporosis, Sjögren’s disease,
chronic eczema, IgA nephropathy
Table 2. Presence of coeliac disease-associated or other co-morbidities during long-term follow-
up in 760 coeliac disease patients without (No repeat biopsy) or with (Repeat biopsy) a follow-up
biopsy done.
No repeat biopsy
n=244
Repeat biopsy
n=516  P-value
 n   %   n %
Associated diseases
Sjögren’s syndrome 1 0 14 3 0.033
Type 1 diabetes 6 3 9 2 0.090
Thyroidal disease 39 16 83 16 0.973
Other conditions
Musculoskeletal  disease 1 66 27 182 36 0.023
Gastroenterological disease 2 78 32 203 40 0.049
Gynecological disease 39 16 103 20 0.198
Neurological disease 29 12 67 13 0.671
Psychiatric disease 11 5 25 5 0.834
Any malignancy 9 4 24 5 0.547
Any fracture 68 28 141 28 0.857
No comorbidities 38 16 58 11 0.079
1e.g. arthritis, osteoporosis, back pain
2e.g. reflux, lactose intolerance, gastritis
Table 3. Long-term follow-up data on 760 coeliac disease patients without (No repeat biopsy) or
with (Repeat biopsy) a control biopsy done while on a gluten-free diet
No repeat
biopsy n=244
Repeat biopsy
n=516 P- value
n % n %
Received dietary advice 231 95 492 95 0.683
Capable of managing  gluten-free diet 216 89 480 94 0.002
Strictness of  gluten-free diet 0.374
Strict diet 231 96 499 98
Occasional lapses 9 4 11 2
Normal gluten intake 0 0 0.0 0
Endomysial antibody titers on  gluten-
free diet 0.012
High 1: >200 12 5 7 1
Low 1:5-1:200 20 9 38 7
Negative 1: <5 189 86 486 92
transglutaminase-2 antibody positivity
on gluten-free diet 39 16 57 11 0.139
Current symptoms 0.268
None 155 78 199 72
Slight 37 19 70 25
Serious 5 3 7 4
Table 4. Gastrointestinal symptoms and quality of life during long-term follow-up in 760 coeliac
disease patients with (Repeat biopsy) or without (No repeat biopsy) a follow-up biopsy done.
No repeat biopsy
n=244
 Repeat biopsy
 n=516 P- value
Median Quartiles Median Quartiles
GSRS sub-scores
Total 1.8 1.5-2.5 1.9 1.5-2.6 0.052
Indigestion 2.3 1.8-3.2 2.5 1.8-3.0 0.046
Diarrhea 1.3 1.0-2.3 1.7 1.0-2.0 0.128
Abdominal pain 1.7 1.3-2.7 2.0 1.3-2.3 0.150
Constipation 1.7 1.0-2.7 1.8 1.0-2.7 0.323
Reflux 1.5 1.0-2.0 1.5 1.0-2.0 0.468
SF-36 sub-scores
Bodily pain 78 53-90 68 48-90 0.013
Physical functioning 95 80-100 90 75-100 0.043
Role limitations, emotional 100 67-90 100 67-88 0.127
General health perception 65 45-80 60 45-75 0.196
Role limitations, physical 100 25-100 75 50-100 0.223
Vitality 75 53-85 70 55-80 0.583
Social functioning 90 75-100 88 75-100 0.634
Mental health 84 72-100 80 72-100 0.978
PGWB  sub-scores
Total 107 95-117 106 94-115 0.515
General health 14 10-15 13 11-16 0.147
Well-being 17 15-20 18 15-19 0.745
Vitality 18 16-20 18 15-21 0.746
Anxiety 25 21-27 25 21-27 0.810
Depression 17 15-18 17 15-18 0.941
Self-control 16 14-17 16 13-17 0.958
GSRS, Gastrointestinal Symptom Rating Scale, lower scores indicate fewer gastrointestinal
symptoms; PGWB, Psychological General Well-Being, higher scores indicate better well-being;
SF-36, Short Form 36, higher scores indicate better social functioning
Table 5. Long-term follow-up characteristics in 476 coeliac disease patients with (Recovery) or
without (Atrophy) histological response at follow-up biopsy.
Atrophy
n=200
Recovery
n=276  P- value
n % n %
Received dietary advice 154 77 215 78 0.683
Capable of managing gluten-free
diet 184 92 264 95 0.820
Strictness of  gluten-free diet 0.060
Strict 195 97 275 100
Occasional lapses 5 3 1 0
Normal gluten use
Use of oats 162 81 231 82 0.947
Regular follow-up 131 66 198 71 0.426
Transglutaminase-2 antibody
positivity 45 23 79 28 0.497
Any malignancy 9 5 14 5 0.762
Fractures 53 27 80 28 0.859
